DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/7xqwcl/guillainbarre) has announced the addition of the "Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" report to their offering.
"Guillain-Barre Syndrome Global Clinical Trials Review, H1, 2014" provides data on the Guillain-Barre Syndrome clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Guillain-Barre Syndrome. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Guillain-Barre Syndrome.
Scope
- Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations
- Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type
-
Listings of discontinued trials (suspended, withdrawn and terminated)
Clinical Trial Overview of Top Companies
- Harvard Pilgrim Health Care, Inc.
- GlaxoSmithKline plc
- CSL Limited
Clinical Trial Overview of Top Institutes / Government
- Erasmus MC
- FDA Office of Orphan Products Development
- Chhatrapati Shahuji Maharaj Medical University
- Mansoura University
- University Medical Centre Ljubljana
- University of Versailles
- University of Cologne
- NHS Greater Glasgow and Clyde
- National Taiwan University Hospital
For more information visit http://www.researchandmarkets.com/research/7xqwcl/guillainbarre
